AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1738926
Drug: Steroid-resistant rejection
RxNorm normalized name: Tumor rejection antigen AB
DrugBank: Tyrosinase (DB16626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-resistant rejection
Trial: 1738926
Drug: 1 year
RxNorm normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 year SCr for patients with steroid-sensitive rejection
Trial: 1738926
Drug: 1 year
RxNorm normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 year SCr for patients with steroid-resistant rejection
Trial: 30502047
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg daily plus P2Y12 inhibitor monotherapy (Group 1)
Trial: 30502047
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg twice daily plus dual antiplatelet therapy (DAPT) (Group 2)
Trial: 30502047
Drug: Standard-of-care vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care vitamin K antagonist and DAPT (Group 3)
Trial: 28447159
Drug: Short-term adjunctive
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term adjunctive antiarrhythmic drug therapy with amiodarone (group A) for the first 3 months
Trial: 28447159
Drug: No antiarrhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiarrhythmic drug therapy except for beta blockers (group B)
Trial: 28447159
Drug: Short-term adjunctive
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term adjunctive antiarrhythmic drug therapy with amiodarone (group A)
Trial: 27515716
Drug: FPG of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPG of 5.5-6.9mmol/L
Trial: 25060541
Drug: Formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol fumarate (FF) 9.6 μg MDI
Trial: 25060541
Drug: Formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol fumarate (FF) 2.4 μg MDI
Trial: 25060541
Drug: Formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol fumarate (FF) 4.8 μg MDI
Trial: 25060541
Drug: Foradil (FA)
RxNorm normalized name: formoterol fumarate Inhalation Powder [Foradil]
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Foradil (FA) 12 μg
Trial: 23209840
Drug: Alcohol treatment
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol treatment (BACs of 0.048%)
Trial: 23209840
Drug: Alcohol treatment
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol treatment (BACs of 0.082%)
Trial: 23209840
Drug: Alcohol treatment
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol treatment (BACs of 0.10%)
Trial: 23209840
Drug: Alcohol treatment
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol treatment (BACs of 0.00%)
Trial: 20833874
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (suture repair of the injured ligament(s) within the first week after injury, followed by a below‐the‐knee plaster cast for six weeks with full weight‐bearing)
Trial: 20833874
Drug: Functional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional treatment (use of an Aircast ankle brace for three weeks)
Trial: 16416642
Drug: Restylane 0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restylane 0.7 mL
Trial: 16416642
Drug: Hylaform 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hylaform 1.0 mL
Trial: 2239757
Drug: Formula with
RxNorm normalized name: Stress B Formula with C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula with 40% medium-chain triglycerides and added L-carnitine
Trial: 2239757
Drug: Formula with
RxNorm normalized name: Stress B Formula with C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula with 40% medium-chain triglycerides without added L-carnitine
Trial: 31444180
Drug: MRI-based active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI-based active surveillance protocol with standardised triggers for repeated biopsies and radical treatment
Trial: 27509703
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment and aspiration of abscess cavity
Trial: 21943067
Drug: Intensive lifestyle
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive lifestyle modification advice (3-monthly)
Trial: 21943067
Drug: Less-intensive lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less-intensive lifestyle modification advice (12-monthly; control group)
Trial: 18280963
Drug: Separate consultation
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate consultation with an oral and maxillofacial surgeon before surgery
Trial: 17161066
Drug: Invasive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive treatment (PCI)
Trial: 12749435
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (12.5 mg/d for the first 10 days of the cycle)
Trial: 30225967
Drug: Spironolactone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (100 mg/d)
Trial: 1331443
Drug: Lisinopril 10
RxNorm normalized name: lisinopril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10 mg once daily for four weeks
Trial: 1331443
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg once daily for four weeks
Trial: 1331443
Drug: Lisinopril 10-20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10-20 mg once daily for six weeks
Trial: 3904570
Drug: diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac sodium 50 mg tid
Trial: 12118026
Drug: Irinotecan (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (350 mg/m² intravenously for 90 minutes) alone
Trial: 12118026
Drug: Irinotecan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (100 mg/m²) with ketoconazole (200 mg orally for 2 days)
Trial: 12118026
Drug: Irinotecan (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (350 mg/m²) alone
Trial: 8710065
Drug: rIFNA (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFNA (9 million IU intramuscular every other day for 6 months)
Trial: 1495453
Drug: Desmopressin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (oral administration)
Trial: 17327245
Drug: Albendazole (three-monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (three-monthly from age 15 months to 5 years)
Trial: 17327245
Drug: Placebo (three-monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three-monthly from age 15 months to 5 years)
Trial: 11907491
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg almotriptan
Trial: 31871115
Drug: Atezolizumab (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (one dose prior to cisplatin CRT, followed by two doses during CRT)
Trial: 31871115
Drug: Atezolizumab (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (three doses during CRT)
Trial: 30134301
Drug: Gabapentin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (600 mg, orally) administered the night before surgery and 2 hours before anesthesia induction
Trial: 30134301
Drug: Gabapentin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (600 mg, orally)
Trial: 28490565
Drug: ipragliflozin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ipragliflozin (50 mg daily)
Trial: 28490565
Drug: metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin (1000 mg daily)
Trial: 26062822
Drug: Iterative Bayesian
RxNorm normalized name: Babesia microti preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iterative Bayesian PK-guided dosing
Trial: 26062822
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing procedure
Trial: 18575077
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of telmisartan and ramipril
Trial: 9566654
Drug: Movement and
RxNorm normalized name: Centrum Movement and Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Movement and swimming program (swimming sessions twice weekly and group physical activity once weekly, each lasting 30 minutes for 6 months)
Trial: 9566654
Drug: Bobath physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bobath physical therapy (30 minutes, 4 days per week)
Trial: 25955225
Drug: Denosumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (60 mg) and calcitriol adjusted to achieve iPTH < 300 pg/mL
Trial: 23070071
Drug: Cisplatin (CDDP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP), 20 mg/m × 5 days every 21 days (arm A)
Trial: 23070071
Drug: Cisplatin (CDDP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP), 40 mg/m per week (arm B)
Trial: 20032478
Drug: Quercetin 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin 150 mg/d
Trial: 2974769
Drug: Domperidone (DA2-antagonist)
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (DA2-antagonist) with ANP infusion
Trial: 2974769
Drug: Domperidone (DA2-antagonist)
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (DA2-antagonist) with head-down tilt
Trial: 2974769
Drug: ANP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ANP infusion
Trial: 30307945
Drug: Protein-calorie supplement
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-calorie supplement (PCS) plus micronutrient supplement (MNS)
Trial: 30307945
Drug: Micronutrient supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient supplement (MNS) alone
Trial: 28012242
Drug: Nonivamide (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonivamide (0.15 mg per day in 450 mL of a milk shake)
Trial: 26602097
Drug: Cancer vaccine
RxNorm normalized name: Hyperacute pancreatic cancer vaccine
DrugBank: Algenpantucel-L (DB17184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer vaccine prepared from autologous dendritic cells and uveal melanoma RNA
Trial: 23177917
Drug: Office administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office administration of mifepristone
Trial: 21598413
Drug: Panax ginseng
RxNorm normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panax ginseng extract (20 g/day mixed with 200 ml of water, three times/day for seven days prior and four days after exercise)
Trial: 18283204
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg of oral glucosamine sulfate once daily
Trial: 16571285
Drug: SFI pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFI pre-treatment with GP regimen
Trial: 16571285
Drug: SFI post-treatment
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: SFI post-treatment with GP regimen
Trial: 14763252
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy and explanatory psychotherapy (Group 2, 18 patients)
Trial: 10873968
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg twice daily for three months
Trial: 3942304
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg epidural morphine
Trial: 3942304
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg epidural morphine
Trial: 3942304
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 mg epidural morphine)
Trial: 30022244
Drug: Outpatient spa
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient spa therapy
Trial: 30022244
Drug: Inpatient spa
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient spa therapy
Trial: 30022244
Drug: Etodolac treatment
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etodolac treatment
Trial: 26850424
Drug: Corticosteroid in
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid in periarticular injection
Trial: 26850424
Drug: No corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No corticosteroid in periarticular injection
Trial: 24965739
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (n=126)
Trial: 24965739
Drug: Nonsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical treatment (n=117)
Trial: 20347369
Drug: 150-mg monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150-mg monthly oral ibandronate
Trial: 18394048
Drug: levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: levetiracetam (LEV) 3000 mg
Trial: 1383816
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of finasteride per day
Trial: 1383816
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of finasteride per day
Trial: 30369135
Drug: 4HPR-L group
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4HPR-L group
Trial: 26931192
Drug: Probiotics (bifidobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (bifidobacillus and lactobacillus) administered once daily by nasogastric tube from the third day of life
Trial: 15326237
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg/day for 42 days, followed by forced dose escalation to 10 mg/day)
Trial: 9751447
Drug: Hydrocolloidal-based matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocolloidal-based matrix tablet (optimized formulation)
Trial: 9751447
Drug: Existing once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing once-daily diltiazem HC1 product (Dilacor XR 240mg)
Trial: 7917729
Drug: Propofol 8
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 8 mg kg‐1 h‐1 followed by 4 mg kg‐1 h‐1 and fentanyl 15 micrograms kg‐1 (group 1)
Trial: 7917729
Drug: Midazolam 3‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 3‐6 mg and fentanyl 60 micrograms kg‐1 (group 2)
Trial: 3279089
Drug: 5-Methoxypsoralen (5-MOP)
RxNorm normalized name: 5 methoxypsoralen
DrugBank: Bergapten (DB12216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Methoxypsoralen (5-MOP) administered at a high oral dosage (doubled from standard dosage)
Trial: 30847444
Drug: Oral betahistine
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral betahistine
Trial: 16965415
Drug: Mupirocin plus
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin plus hydrocortisone butyrate ointment
Trial: 16965415
Drug: Vehicle ointment
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle ointment plus hydrocortisone butyrate ointment
Trial: 15373933
Drug: St John's
RxNorm normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St John's Wort (SJW) 900 mg day(‐1) for 14 days
Trial: 9253329
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IGF‐I (80 micrograms/kg.day) and GH (0.3 IU/kg.day)
Trial: 8323473
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with dipyridamole (75 mg three times a day) and aspirin (330 mg three times a day)
Trial: 3103983
Drug: Combined blunt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined blunt spatula debridement and trifluridine therapy
Trial: 26080652
Drug: Empagliflozin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 2.5 mg
Trial: 25985246
Drug: PDA-001 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDA-001 (1 unit or 4 units, 2 infusions 1 week apart) in phase 2a study
Trial: 11885184
Drug: Implant length
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant length
Trial: 1540597
Drug: Diltiazem (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (30 mg three times daily increasing to 60 mg three times daily at 1 month)
Trial: 1540597
Drug: No calcium
RxNorm normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No calcium blocker (Control)
Trial: 4048359
Drug: Naloxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (2 mg/kg)
Trial: 28641469
Drug: Counselling (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counselling (6 group sessions, twice per week for 3 weeks)
Trial: 25162603
Drug: DETERx 40-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DETERx 40-mg capsules intact
Trial: 20374034
Drug: Neoadjuvant aromatase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant aromatase inhibitors (AI) for 3 months
Trial: 16062074
Drug: Oxaliplatin 130
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 130 mg/m2 every 21 days
Trial: 7997500
Drug: Newly designed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newly designed partial subperiosteal implants
Trial: 7997500
Drug: Classical design
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical design partial subperiosteal implants
Trial: 31200668
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy from a psychiatric nurse
Trial: 29798368
Drug: Intratympanic injection
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic injection of budesonide (BUD) 0.5 mg/ml
Trial: 29798368
Drug: Intratympanic injection
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic injection of dexamethasone (DEX) 5 mg/ml
Trial: 29798368
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride (NS) solution (1 ml)
Trial: 21977965
Drug: saxagliptin 2.5
RxNorm normalized name: sAXagliptin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saxagliptin 2.5 mg once daily
Trial: 18326612
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg Zn as zinc sulfate
Trial: 18326612
Drug: 7 mg
RxNorm normalized name: pectin 7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 mg Zn as zinc sulfate
Trial: 18326612
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Zn as zinc sulfate
Trial: 18326612
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Zn + 0.5 mg Cu as copper sulfate
Trial: 17726807
Drug: Yasmin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yasmin (3 mg Drospirenone and 30 microg ethinylestradiol)
Trial: 10883875
Drug: SRP+Metro (subgingival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP+Metro (subgingival scaling and root planing with metronidazole 25% dental gel)